Pharming Group N.V. - ADS, each representing 10 ordinary shares (PHAR)

Competitors to Pharming Group N.V. - ADS, each representing 10 ordinary shares (PHAR)

Amgen Inc. 

Pharming Group N.V. and Amgen Inc. both operate in the biotechnology sector, focusing on developing therapies for rare diseases and genetic disorders. Pharming specializes in recombinant human proteins, such as its FDA-approved Ruconest for hereditary angioedema, whereas Amgen's portfolio includes a wider range of biologic drugs targeting various conditions, leveraging its established infrastructure and research capabilities. Although Pharming focuses on niche therapies, Amgen's extensive market reach and significant financial resources give it a competitive advantage in broader therapeutic areas and larger patient populations.

Boehringer Ingelheim

Pharming Group N.V. and Boehringer Ingelheim both participate in the biotechnology sector but differ in scale and product breadth. Boehringer Ingelheim is a major player with a diversified portfolio across human pharmaceuticals and animal health, whereas Pharming focuses specifically on its unique biologic drugs like Ruconest. The extensive R&D capabilities, financial resources, and diversified product pipeline of Boehringer Ingelheim provide it with a significant competitive advantage over Pharming. This allows Boehringer to leverage its expertise across multiple therapeutic areas, potentially reducing the risks associated with failure in a single product line.

Catalent Inc. 

Pharming Group N.V. and Catalent Inc. are also rivals in the biopharmaceutical sector, with both companies involved in advanced drug delivery systems and the production of biologics. While Pharming emphasizes its proprietary technologies for producing therapeutic proteins, Catalent offers comprehensive manufacturing and development services for a wider array of pharma and biotech products. While Pharming has a unique focus on its specific therapies, Catalent's extensive capabilities in drug formulation and commercialization provide a significant edge in the competitive landscape of drug production and supply.

Grifols S.A. 

Pharming Group N.V. and Grifols S.A. compete in the biopharmaceutical and plasma-derived therapies space, addressing the needs of patients with rare diseases through innovative therapies. Grifols has a long-standing reputation in the plasma market, processing and developing therapeutic products from human plasma, which may provide it a more stable revenue model compared to Pharming’s reliance on highly specialized proteins. While both companies possess strength in their niche, Grifols' larger scale and established global footprint give them a competitive advantage in terms of resource allocation and market presence.

Sobi AB

Pharming Group N.V. and Sobi AB both target treatments for rare diseases, especially within the realm of hereditary disorders and niche therapies. Both companies are focused on innovative pharmaceutical solutions, with Pharming providing targeted therapies such as Ruconest, while Sobi specializes in treatments for hemophilia and other rare diseases. Although both companies have a similar target market, Pharming's research into enzymatic therapy for genetic disorders could grant it a competitive advantage in developing new therapies, as well as gaining traction in emerging markets.